Establishment of PDX model of oral cancer and PDX-derived cell lines, and usefulness of anti-HER2 antibody therapy

被引：0
|
作者：
Seki, Yuki [1 ]
Kariya, Ryusho [2 ]
Yoshida, Ryoji [3 ]
Kawahara, Kenta [3 ]
Hirayama, Masatoshi [3 ]
Takahashi, Nozomu [3 ]
Nakamoto, Masafumi [3 ]
Takeshita, Hisashi [3 ]
Okada, Seiji [2 ]
Nakayama, Hideki [3 ]
机构：
[1] Kumamomto Univ, Grad Sch Med Sci, Kumamoto, Japan
[2] Kumamoto Univ, Div Hematopoiesis, Joint Res Ctr Human Retrovirus Infect, Kumamoto, Japan
[3] Kumamoto Univ, Dept Oral & Maxillofac Surg, Fac Life Sci, Kumamoto, Japan
来源：
CANCER SCIENCE | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2325
引用
收藏
页码：1074 / 1074
页数：1
相关论文
共 50 条
  • [31] Prospect for anti-HER2 receptor therapy in breast cancer
    Brand, FX
    Ravanel, N
    Gauchez, AS
    Pasquier, D
    Payan, R
    Fagret, D
    Mousseau, M
    ANTICANCER RESEARCH, 2006, 26 (1B) : 463 - 470
  • [32] Anti-HER2 therapy for breast cancer in older patients
    Goldner, Marcelle
    Franzoi, Maria A.
    Lago, Lissandra D.
    Ponde, Noam
    FUTURE ONCOLOGY, 2020, 16 (19) : 1393 - 1407
  • [33] Trastuzumab: Anti-HER2 antibody for treatment of metastatic breast cancer
    Wong, WM
    CANCER PRACTICE, 1999, 7 (01) : 48 - 50
  • [34] Current and future anti-HER2 therapy in breast cancer
    Vrbic, S.
    Pejcic, I.
    Filipovic, S.
    Kocic, B.
    Vrbic, M.
    JOURNAL OF BUON, 2013, 18 (01): : 4 - 16
  • [35] Anti-HER2 Therapy in Elderly Breast Cancer Patients
    Sawaki, Masataka
    REVIEWS ON RECENT CLINICAL TRIALS, 2014, 9 (04) : 263 - 266
  • [36] Advances in anti-HER2 therapy in metastatic breast cancer
    Yao, Minya
    Fu, Peifen
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [37] Optimising anti-HER2 therapy in early breast cancer
    Piccart, M.
    Bedard, P.
    de Azambuja, E.
    EJC SUPPLEMENTS, 2009, 7 (02): : 34 - 34
  • [38] The perspective of anti-HER2 therapy for HER2 positive breast cancer
    Iwata, Hiroji
    ANNALS OF ONCOLOGY, 2015, 26 : 11 - 11
  • [39] Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition
    Asmerom T. Sengal
    Vanessa Bonazzi
    Deborah Smith
    Cristian P. Moiola
    Rohan Lourie
    Rebecca Rogers
    Eva Colas
    Antonio Gil-Moreno
    Sophia Frentzas
    Naven Chetty
    Lewis Perrin
    Pamela M. Pollock
    npj Precision Oncology, 7
  • [40] Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer
    Takahito Masuda
    Hiroshi Fujimoto
    Ryotaro Teranaka
    Masayuki Kuroda
    Yasuyuki Aoyagi
    Takeshi Nagashima
    Takafumi Sangai
    Mamoru Takada
    Ayako Nakagawa
    Yoshitaka Kubota
    Koutaro Yokote
    Masayuki Ohtsuka
    Breast Cancer Research and Treatment, 2020, 180 : 625 - 634
12345